CompanyGraph
Tibet Cheezheng Tibetan Medicine Co. Ltd.
002287 · SZSE · China
cheezheng.com.cnFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.73B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.32: safe zone
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.01%Below 5Y avg (2.07%)
Annual Rate
CNY 0.41Paid annual
Payout Ratio
49.2%Sustainable
Payback Period
48.4 yr
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
11.64BCNY1.73B · vs all stocks (USD)
Trailing P/E
16.67xvs Biotechnology peers
Revenue (TTM)
2.42BCNY358.63M · vs all stocks (USD)
Profit Margin
27.62%vs Biotechnology peers
Beta
0.1450xvs all stocks
52-Week Change
-29.71%vs all stocks
Market Capitalization
11.64BCNY1.73B · vs all stocks (USD)
Enterprise Value
9.85BCNY1.46B · vs all stocks (USD)
Trailing P/E
16.67xvs Biotechnology peers
Forward P/E
19.56xvs Biotechnology peers
Price to Sales (TTM)
4.81xvs Biotechnology peers
Price to Book (MRQ)
2.29xvs Biotechnology peers
Enterprise to Revenue
4.08xvs Biotechnology peers
Enterprise to EBITDA
13.42xvs Biotechnology peers
Gross Margin
83.93%vs Biotechnology peers
Profit Margin
27.62%vs Biotechnology peers
Operating Margin
22.20%vs Biotechnology peers
Return on Assets (TTM)
5.58%vs Biotechnology peers
Return on Equity (TTM)
14.55%vs Biotechnology peers
Revenue (TTM)
2.42BCNY358.63M · vs all stocks (USD)
Revenue per Share (TTM)
4.38CNYUpdated Aug 19, 2026Quarterly Revenue Growth
0.60%vs Biotechnology peers
Gross Profit (TTM)
2.02BCNY299.11M · vs all stocks (USD)
EBITDA (TTM)
746.85MCNY110.76M · vs all stocks (USD)
Net Income (TTM)
667.92MCNY99.05M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
25.80%vs Biotechnology peers
Operating Cash Flow (TTM)
310.41MCNY46.03M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-220.92MCNY-32.76M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.4100CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
2.01%vs all stocks
5-Year Average Dividend Yield
2.07%vs all stocks
Payout Ratio
49.24%vs Biotechnology peers
Minority Interest (Equity)
47.93MCNYFY2025 · Dec 31, 2025Revenue
2.42BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
409.47MCNYFY2025 · Dec 31, 2025Gross Profit
2.01BCNYFY2025 · Dec 31, 2025Operating Income
729.64MCNY108.21M · vs all stocks (USD)
Pre-tax Income
739.84MCNYFY2025 · Dec 31, 2025Income Tax Expense
92.37MCNYFY2025 · Dec 31, 2025Net Income
647.47MCNYFY2025 · Dec 31, 2025EBIT
781.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
850.80MCNYFY2025 · Dec 31, 2025Research & Development
81.03MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
859.36MCNYFY2025 · Dec 31, 2025Other Operating Expenses
39.80MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.78MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
41.86MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.19CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.19CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
543.53MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
543.53MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
647.47MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
951.31KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
581.50MCNYFY2025 · Dec 31, 2025Free Cash Flow
428.81MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
376.09MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
647.47MCNYFY2025 · Dec 31, 2025Other Non-cash Items
37.76MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
12.29MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-116.03MCNYFY2025 · Dec 31, 2025Capital Expenditures
-152.69MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.34BCNYFY2025 · Dec 31, 2025Sale of Investments
1.51BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
20.99MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
961.58MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-931.10MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-453.04MCNYFY2025 · Dec 31, 2025Other Financing Charges
-141.52MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-564.08MCNYFY2025 · Dec 31, 2025Shares Outstanding
572.12MSharesUpdated Aug 19, 2026Float Shares
101.78MSharesUpdated Aug 19, 2026% Held by Insiders
82.31%vs all stocks
% Held by Institutions
0.45%vs all stocks
Total Cash (MRQ)
2.66BCNY393.78M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.68CNYUpdated Aug 19, 2026Total Debt (MRQ)
807.83MCNY119.80M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1588xvs Biotechnology peers
Current Ratio (MRQ)
3.12xvs Biotechnology peers
Book Value per Share (MRQ)
8.89CNYUpdated Aug 19, 2026Total Assets
6.92BCNY1.03B · vs all stocks (USD)
Total Current Assets
4.31BCNYFY2025 · Dec 31, 2025Total Liabilities
1.92BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.61BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
242.13MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.68BCNYFY2025 · Dec 31, 2025Cash
376.09MCNYFY2025 · Dec 31, 2025Cash Equivalents
349.04KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
376.44MCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.57BCNYFY2025 · Dec 31, 2025Accounts Receivable
99.52MCNYFY2025 · Dec 31, 2025Inventory
294.11MCNYFY2025 · Dec 31, 2025Accounts Payable
204.74MCNYFY2025 · Dec 31, 2025Short-term Debt
922.94MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.87MCNYFY2025 · Dec 31, 2025Long-term Debt
6.90MCNYFY2025 · Dec 31, 2025Common Stock (Book)
572.12MCNYFY2025 · Dec 31, 2025Retained Earnings
2.52BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.00BCNY740.85M · vs all stocks (USD)
Treasury Stock
137.45MCNYFY2025 · Dec 31, 202552-Week Low
18.33CNYUpdated Aug 19, 202652-Week High
29.34CNYUpdated Aug 19, 202652-Week Change
-29.71%vs all stocks
Beta
0.1450xvs all stocks
50-Day MA
20.35CNYUpdated Aug 19, 2026200-Day MA
22.91CNYUpdated Aug 19, 2026Avg 10-Day Volume
2.63MSharesUpdated Aug 19, 2026Avg 30-Day Volume
3.19MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
1.22CNYUpdated Aug 19, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 99,053,228.858Operating Cash Flow (USD, TTM): 46,033,321.322
Financial Health
Altman Z-Score 5.32: safe zoneNotable
Altman Z-Score: 5.32
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.73B, above the global median of $1.15BNotable
Market cap (USD): 1,725,749,934.127Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Butterfly Network Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Harrow Inc.
Tier 1ProductionApproval-Gated PipelineRule
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Classys Inc.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
Pharma Research Products Co., Ltd
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
Shanghai Bochuan Electronic Co., Ltd.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin